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CONNECTIVE TISSUE ACTIVATION 
IX. MODIFICATION BY PHARMACOLOGIC AGENTS 
C. WILLIAM CASTOR 
With the Technical Assistance of 
MARY E. SCOTT, JAMES C. RITCHIE, and SANDRA C. HARNSBERGER 
Alpha- and beta-adrenergic blocking agents and 
imipramine inhibit the increased hyaluronate synthesis 
that may be induced in human synovial cultures b y  
connective tissue activating peptide (CTAP). Consid- 
erations of drug concentration requirements, actions 
of analogues, and time studies all indicate that the 
adrenergic blockers do not act in this circumstance as 
conventional blockers of alpha or beta receptor sites. 
It is suggested that the membrane-stabilizing proper- 
ties of these agents may be the important determinant 
for their limited “antiactivation” effect. Ethacrynic 
acid, a potent and more complete inhibitor of con- 
nective tissue activation, appears to act via a different 
mechanism. 
Earlier reports described a connective tissue 
activating peptide (CTAP) that is extractable from 
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human cells and capable of inducing increased meta- 
bolic activity in  cultured synovial cells resembling the 
altered metabolic activity attributed to the synovial 
membrane in rheumatoid synovitis (1-4). CTAP has a 
molecular weight between 10,000 and 15,000 daltons, 
may be extracted from many cell types, and, when 
placed in contact with normal human synovial cells, 
induces metabolic consequences (connectiue tissue 
activation) including: hyperproduction of low mole- 
cular weight hycllirronic acid, increased glucose up- 
take, and uccelerated lactic acid production. This con- 
stellation of phenomena clearly mimics those docu- 
mented for rheumatoid synovitis in vivo, including 
the findings of excessive amounts of low molecular 
weight hyaluronic acid in joint fluid ( 5 ) ,  decreased 
joint fluid PO, pH, and increased lactate concentra- 
tions (6). Studies showing that several commonly used 
antirheumatic drugs block connective tissue activation 
suggested that this in vitro system might be useful as 
a human model for specific components of the inflam- 
matory process, and might be valuable for screening 
potential antiinflammatory agents and determining 
their site of action (7). 
Although the mechanism of action of CTAP is 
not fully understood, current thinking of these authors 
is summarized in Figure 1, where CTAP is shown 
interacting with a complex cell membrane receptor 
site possessing at least two distinct components. At 
the bottom of the illustration the ultimate conse- 
quences of CTAP interaction with a synovial cell are 
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I PROTEIN SYNTHESIS 
/ Glucose Source /' 
GI~UA-+ HYALURONATE(4) 
Fig 1. This  scheme suggests that activation of a synovial cell involves triggering two essential 
and independent reaction sequences leading ultimately to accelerated glycolysis and increased 
hyaluronic acid synthesis. 
shown as  increased glycolysis and hyaluronic  acid for- 
mat ion.  A segment  of t h e  metabol ic  events following 
interact ion of CTAP w i t h  a cell membrane receptor  
site may be visualized in relat ion t o  C o m p o n e n t  I 
where i t  has  been shown t h a t  b o t h  m R N A  synthesis 
and pro te in  synthesis are requi red  for t h e  act ivat ion 
process, because t h e  inh ib i tors  of these events clearly 
block the  act ion of CTAP (8). C o m p o n e n t  I1 of t h e  
receptor  s i te  mechanism m a y  al ter  the  synthesis of 
cellular prostaglandins ,  and t h e  subsequent  accumula-  
t ion  of synovial cell cyclic AMP m a y  serve t o  mobilize 
energy and carbon for hyaluronate  synthesis. Com- 
p o n e n t  I1 of t h e  CTAP-synovial  cell in te rac t ion  is 
blocked by indomethac in  (9); i t  is likely most  of t h e  
o ther  ant i inf lammatory organic  acids act  a t  this  site. 
In t h e  context  of this background,  several phar- 
macologic agents, inc luding  adrenergic blocking 
agents, have been examined  by the  a u t h o r s  for the i r  
effect on t h e  capacity of CTAP t o  s t imula te  h u m a n  
synovial cultures. 
MATERIALS AND METHODS 
Synovial membranes were obtained a t  arthrotomy or  
amputation and a portion of the tissue was fixed for his- 
tologic examination. T h e  remainder of the tissue was di- 
vided into small fragments and used to generate cell cul- 
tures by methods reported previously (10). Cell strains used 
in  this study were derived either from normal synovial 
membranes or  from patients with degenerative joint disease 
or traumatic synovitis. Synovial cells from patients with 
these latter two entities had similar growth and biochemical 
parameters (10). Routine culture growth medium consisted 
of 80% synthetic medium 1066 (Grand Island Biological 
Company, Grand Island, New York), 10% fetal calf serum, 
and lOO/b heat-inactivated human serum, and was supple- 
mented with L-glutamine, penicillin, and streptomycin. 
Human serum was inactivated by incubation at 56°C for 
1 hour. Cells were enumerated and sized with a Coulter 
model B cell counter (Coulter Electronics, Hialeah, Florida). 
Synovial tissue fragments and suspensions of synovial fibro- 
blast-like cells were stored by freezing with 6% dimethyl- 
sulfoxide in standard medium as reported earlier (10). 
Culture protein was measured by the method of 
Oyama and Eagle (1 I ) ,  glucose by a glucose oxidase method 
(12), and lactate by the Barker-Summerson procedure (13). 
Hyaluronic acid in  non-serum-containing medium was iso- 
lated using cetylpyridinium chloride without prior proteo- 
lysis (14), and uronic acid was determined by a carbazole 
method ( 1  5). 
CTAP used in these experiments was prepared from 
normal human spleen, from HEp., tissue culture cells, and 
from normal human leukocytes by methods reported pre- 
viously (16). Most of the CTAP preparations were hetero- 
geneous by polyacrylamide gel electrophoresis. 
In typical tissue culture experiments, 1 x 106 
normal synovial cells were placed in T-I5  flasks containing 
2.0 ml of standard serum-containing medium. After 4 to 6 
hours incubation at 37"C, the initial medium was replaced 
with 2 ml of Eagle's synthetic medium, buffered to pH 
7.4 with 0.02 M Hepes (N-2-hydroxyethylpiperazine-h~-2- 
ethanesulfonic acid, Calbiochem, Los Angeles, California) 
buffer Supplemented with penicillin, streptomycin, and L- 
glutamine. Experimental Hasks received 0 .1  to 0.3 ml of 
test materials and control flasks received an equivalent 
volume of the appropriate vehicle. Vehicles utilized in- 
cuded 0.001 hf dithiothreitol and 0.001 A4 cysteine. Flasks 
were incubated a t  3 5 4 7 ° C  for 40 hours and then measure- 
ments were made of total cell protein, total medium hya- 
luronic acid, total medium glucose, and lactic acid. T h e  
hyaluronic acid synthesis rate was expressed in  micrograms 
of hyaluronic acid per milligram of cell proteiir per 24 
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PROPRANOLOL INHIBITION OF HYALURONATE SYNTHESI 5 
IN  SYNOVIAL CULTURES 
0 loe6 M M M 
P ropranolol Concentration 
Fig 2. dl-Propranolol exhibits a dose-dependent capacity to in- 
hibit hyaluronate synthesis in CTAP-activated synovial cultures. 
Data are plotted as mean t 1 SD. 
hours; glucose uptake and lactate formation were expressed 
in micromoles per milligram of cell protein per 24 hours. 
Experimental groups consisted of two to four flasks and 
the data were expressed in terms of means 2 1 SD. 
Chlorpromazine, haloperidol, phenoxybenzamine, al- 
prenolol, and practolol were obtained from commercial 
sources. Butoxamine (lot 47162) was a gift of the Bur- 
roughs Wellcome Company, Kesearch Triangle Park, 
North Carolina. Phentolamirie hydrochloride (K-6835) and 
imipramine were kindly provided by the Ciba Pharmaceu- 
tical Company, Summit, New Jersey. l'ropranolol hydro- 
chloride (81-6474-1) was a gift from the Ayerst Laboratories, 
New York, New York. Albuterol (C5052) was provided by 
the Schering Corporation, Kenilworth, New Jersey, and L- 
isoproterenol hydrochloride was purchased from the Sigma 
Chemical Company, St. Louis, Missouri. Ethacrynic acid 
was a gift from Merck, Sharp and Dohme Research Labora- 
tory, Rahway, New Jersey. The  dimethylquaternary deriva- 
tive of propranolol was made available by Dr. Benedict 
Lucchesi, Professor of Pharmacology, University of Michigan 
Medical School, Ann Arbor, Michigan. 
RESULTS 
Effects of Alpha- and Beta-Adrenergic Blocking 
Agents. As shown in  Figure 2, propranolol, a beta,,, 
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Fig 3. dl-Propranolol did not suppress lactate formation in 
CTAP-activated synovial cultures. 
blocking agent, had  a minor suppressive effect on  
hyaluronate formation in  unstimulated synovial 'cul- 
tures. O n  the other hand, CTAP-stimulated cultures 
were progressively inhibited with respect t o  hyaluro- 
nate formation as propranolol was increased from 
M to lo-' M ,  and  a t  the latter concentration 
formation of incremental hyaluronate was nearly 
abolished. Figure 3 shows that propranolol had little 
effect o n  CTAP-stimulated formation of lactic acid. 
O n  the other hand, in control cultures the highest 
concentrations of propranolol actually stimulated 
lactic acid formation. I n  the same vein, Figure 4 
shows that CTAP-stimulated uptake of glucose was 
also virtually unaffected by propranolol. As with lac- 
tate production, the highest concentration of pro- 
pranolol had  a modest tendency to stimulate glucose 
uptake when used alone. The effects of alprenolol (a 
beta,,, blocking agent similar to propranolol) and  
butoxamine (primarily a beta, blocking agent) are de- 
picted i n  Figure 5. T h e  vehicle, alprenolol, and  
butoxamine, added singly, had  no effect o n  incre- 
mental  hyaluronate synthesis, whereas maximal stim- 
ulation was achieved with CTAP.  Alprenolol 
M )  added with C T A P  caused 50% inhibition of 
C T A P  stimulation. T h e  effect of increasing concen- 
trations of butoxamine o n  C T A P  stimulation is 
shown. Inhibit ion of C T A P  stimulation was marked 
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PROPRANOLOL EFFECT ON GLUCOSE UPTAKE I N  SYNOVIAL CULTURES 
8.0 r 
0 M 10'~ M M 
Propranolol Concentration 
Fig 4. Glucose consumption in CTAP-activated synovial cul- 
tures was not influenced by dl-pro~iranolol. 
at M ,  minimal at  lo-: M ,  and absent at lo-" M .  
Similar data concerning representative adren- 
ergic blocking agents are exhibited in Figure 6. In  
this experiment, butoxamine (lo-' M )  completely in- 
hibited CTAP-induced incremental hyaluronate syn- 
thesis. Propranolol, the prototype beta,., blocker, had 
the same inhibitory effect at lo-' M ,  but interestingly 
practolol, a beta, blocking agent, had essentially no 
inhibiting effect on the activating capacity of CTAP. 
Of considerable interest was evidence that phentola- 
mine, an  alpha blocking agent, also was markedly 
inhibitory at  M .  Other alpha blocking agents 
having a potent inhibitory effect on synovial cell acti- 
vation included clilorpromazine, haloperidol, phen- 
oxybenzamine, and several experimental alpha-adren- 
ergic blocking agents. In  summary, in the limited 
group of drugs tested, adrenergic agents with either 
beta, or alpha blocking activity inhibited CTAP acti- 
vation of synovial cells at concentrations of M 
to 1 0 - 5  M .  
Because the concentrations of blocking agents 
required to inhibit synovial cell activation were so 
high (lo-; M to lo-' M ) ,  it was suspected that some- 
thing other than typical blockade of alpha- or beta- 
adrenergic receptor sites was involved in this pharma- 
cologic action. Table 1 shows the inhibitory effect of 
propranolol given simultaneously with CTAP (at 0 
time) and 16 hours following CXAP treatment of 
synovial cells. Propranolol alone had no effect on 





Vehicle Alprenolol Butox CTAP CTAP CTAP CTAP CTAP 
t t + + 
Alpren Butox Bulox Butox ~ o - ~ M  ~ o - ~ M  
M ~ o - ~ M  ~ O + M  ~ o - ~ M  
Fig 5. Both alprenolol, a beta,,, adrenergic blocking agent, and 
butoxamine, a betaz blocking agent, rnarkedly inhibit incre- 
mental hyaluronate synthesis in CTAP-activated synovial cul- 
tures. Incremental hyaluronrite synthesis rnte reflects that in- 
crease in H A  synthesis (FgHAlmg cell proteinl2.f hours) caused 
by a stimulatory agent. I n  this figure and Figure 6, the agonist 
was CTAP and the increment in H A  synthesis due to this agent 
uws arbitrarily set at 100yo. 




Vehicle CTAP CTAP CTAP CTAP CTAP 
t + + t 
Butox Propran Practolol Phentol 
~ o - ~ M  ~ o - ~ M  ~ o - ~ M  ~ o - ~ M  
a Type of Blocker----------- B? 8 1 . 2  B1 
Fig G .  Practolol, a beta, adrenergic blocking agent, was without 
eflrrl on CT.4P-actirwterl synovial cultures, but beta,,,, beta,, 
and alplza blocking agents were niarkedly inhibitory. 




Propranolol, 10- M 
Propranolol, lo--‘ M 
CTAP* 
CTAP 4- propranold 
CI’AP + propranolol 
Table 1. Effect of dl-Propranolol on Activated Synovial Cells 
Hyaluronate 
Time of Glucosc Uptake Lactate Output Synthesis Rate 
(hr) protcin/24 hr) protcin/24 hr) protein/24 hr) 
1.2 t 0.8 - 0.18 4.03 f 1.10 
0 1.06 -C 0.45 3.27 f 1.60 0.6 +. 0.5 
16 1.70 ? 0.84 2.56 f 1.43 1.2 t 1.4 
0 3.74 -C 1.82 8.47 t 0.95 57.2 k 18.1* 
0 2.71 t 1.31 11.77 k 1.23 18.0 f 1.8 
16 4.06 t 1.49 12.33 +. 1.07 34.0 f 4.9t  
Addition (pmoles/mg cell (rmoles/mg cell ( W m g  cell 
Fresh mctlium was atltlctl to normal synovial cell strain TC.  ninth passage at 16 hours after addition of CTAP. 
tll-Propraiinlol \\as atltlctl at  zcio tinic to one group of activated flasks, and at 16 hours to a second group of 
activated flasks. 
*CTAP was tlcrivctl from HEp+ 
+The tliffercnce is significant at P < 0.05. 
hyaluronate synthesis, whereas CTAP caused a 47- 
fold increase in hyaluronate. Propranolol (lo-‘ M) 
added simultaneously with Cl‘AP inhibited incre- 
mental Iiyaluronate synthesis by 70%. When pro- 
pranolol was added I6 hours after CTAP, presumably 
long after the initiatory events at the receptor site, 
inhibition of incremental hyaluronate formation was 
still observed, although the effect was not as great 
as that at zero time. It thus appears that propranolol 
interferes with events subsequent to the initiating 
membrane phenomena. To clarify whether the adren- 
ergic blocking agents acted after that early portion of 
the activation sequence involving prostaglandin and 
cyclic AMP, the effect of propranolol and chlorproma- 
ADRWERGIC INTERFERENCE WITH PGE 1 AND db CAMP STIMULATION 




Vehicle P G E l  P G E l  P G E l  dbcAMP dbcAhnr , , C A M P  
5 p g 1 m l  + t 1 . O p M  + + 
Propran Chlorprom Proprar  tlorprom 
~ o - ~ M  M 10-4M 
zine on stimulated hyaluronate synthesis caused by 
high concentrations of PGE, and dibutyryl cyclic 
AMP was examined (Figure 7). Control cultures syn- 
thesized minor amounts of hyaluronate, whereas PGE, 
and tlil,utyryl cyclic AMP stimulated substantial in- 
crements in Iiyaluronic acid. Propranolol and chlor- 
promazine both markedly depressed PGE, stimulation 
of synovial cells. In  the same vein, both adrenergic 
blocking agents also suppressed tlibutyryl cyclic AMP 
stimulation of hyaluronic acid synthesis in synovial 
cells. 
Failure of Adrenergic Agonists to Stimulate 
Synovial Cells. Isoproterenol, a potent beta-adrenergic 
agonist, was added to synovial cultures in the abscence 
of serum at concentrations of M and M 
without measurable alteration of hyaluronate forma- 
tion or glycolysis. Simultaneous addition of theophyl- 
lin (0.5 x lo-“ M)  with isoproterenol also did not 
result in stimulation of synovial cells. Albuterol, a 
beta, agonist, failed to stimulate hyaluronate syn- 
thesis or glycolysis in  concentrations of 4 x M 
and 1.3 x lo-“ M. Epinephrine (1 x lo-‘ M )  was 
also ineffective in stimulating these parameters in  
human synovial cell cultures. 
Relative Importance of Beta Blocking, Local 
Anesthetic, and Membrane Stabilizing Properties. 
Further evidence that the “antiactivation” effects of 
adrenergic blocking agents are not coupled to beta 
blocking ability is found in Table 2. l h e s e  data show 
that d-propranolol, a relatively ineffective beta block- 
ing agent ( l i ) ,  is similar to tll-propranolol in its 
capacity to inhibit synovial cell activation. On  the 
other hand, UM-2i2 (a tlimethyl quaternary deriva- 
tive of propranolol) was a weaker inhibitor of synovial 
cell activation. In  three further experiments the “anti- 
Fig 7 .  Both PGE, and dibutyryl cyclic AAIP i n  ; . : . . / I  co~icen-  
trations stimulate synovial cell Irsnluronate synfhesi..  T h i s  stim- 
ulation was effectively elir,rinated in  6011~ cases 6, .  d! ~ , r o ~ r a n o l o l  
and chlorproniazine. activation” potency of UM-272 ranged from zero to 
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Table 2. Eflect of dl-Propranolol, d-Propranolol, and a 
Quaternary Propranolol Derivative on Synovial Cell Activation 
Additives 
Vehicle 
dl-Propranolol, lo4 M 
d-Propranolol, lo4 M 
UM-272, lo+ M 
CTAP 
CTAP f dl-propranolol 
CTAP + d-propranolol 




3.70 f 0.14 
4.71 f 0.66 
4.83 +- 0.13 
4.00 + 0.72 
7.40 f 0.14 
6.70 f 0.47 
6.79 f 0.21 




4.30 f 0.68 
6.87 t 0.65 
7.91 f 1.33 




9.7 f 0.4 
7.6 f 0.4 
8.2 f 0.5 
8.5 f 1.5 
(pglmg cell 
12.82 +- 2.37 
11.67 f 2.09 
12.74 f 0.56 
13.26 f 1.67 
20.2 f 1.7 
12.5 * 1.8* 
11.4 f 0.2* 
16.5 f 2.3t 
*Depression below activated (CTAP) values was significant at P < 0.01. 
$The minor depression in activation in the presence of UM-252 was significant at P < 0.05. 
minimal. These observations are of interest because 
UM-272, although possessing antiarrliythmic proper- 
ties, does not have demonstrable beta-adrenergic re- 
ceptor blocking or local anesthetic activity (18). 
Because it seemed unlikely that the adrenergic 
blocking agents exerted their effect on activation by 



























































































Lidocaine Lidocai n e Lidocai n e  
1 0 - 5 ~  ~ o - ~ M  ~ o - ~ M  
Fig 8. Although both procaine and lidocnine inhi6it C T A P -  
activated synovial culture synthesis of hyaluronic acid, ten times 
as much drug is required as in the c a x  of p r o ~ m n o l o l  and the 
other adrenergic blocking agents. 
conventional blockade of alpha and beta receptor 
sites, and because these agents are known to have 
potent membrane stabilizing effects (local anesthetic 
effects), model experiments were carried out with pro- 
caine and lidocaine, both potent local anesthetics 
characterized by marked membrane stabilizing activity. 
Neither procaine nor lidocaine was a very effective 
agent in suppressing CTAP activation of synovial cells 
(Figure 8). CTAP caused a threefold increase in hya- 
luronate synthesis and procaine M )  had little 
suppressive effect. Lidocaine M and lo-" M )  
had no inhibitory effect and was only moderately 
inhibitory at lo-:' M. Thus procaine and lidocaine 
were only one-tenth as potent as dl-propranolol and 
other adrenergic-blocking agents in opposing the acti- 
vation process. 
Actions of Imipramine and Ethacrynic Acid. 
Imipramine, an antidepressant with marked local anes- 
thetic properties, was a potent inhibitor of synovial 
cell activation. As shown in Table 3, incremental 
1iyaluronat.e following either CTAP or dibutyryl 
cAhIP was markedly reduced by imipramine, lo-' M. 
Glucose uptake and lactate formation were stimulated 
by imipramine added alone, but the drug did not 
modify CTAP alteration in these parameters. 
Etliacrynic acid (0.83 x lo-' M )  resembled 
imipramine in that addition of the drug at zero time 
blocked incremental hyaluronate synthesis in synovial 
cultures stimulated by either CTAP or dibutyryl 
CAMP (Table 4). Unlike imipramine antl the adren- 
ergic blocking agents, etliacrynic acid interfered with 
Cl'AP-stimulated glycolysis. An experiment showing 
the effect of time of addition of tlirce drugs is shown 
in Table 5. When (11-propranolol, imipramine, antl 
etliacrynic acid were added simultaneously with 
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Glucose Uptake Lactate Output Synthesis Rate 
(pmoleslmg cell (amoles/mg cell (rg/,mg cell 
protein/24 hr) protein/24 hr) protein/24 hr) 
Vehicle 3.28 f 0.14 4.22 f 0.14 7.5 c 0.2 
Imipramine, 10+ M 4.27 f 0.22 7.06 f 0.80 6.5 f 1.1 
CTAP 4.75 f 0.06 7.40 f 0.27 16.2 f 1.6 
CTAP f imipramine, 10- M 4.87 f 0.15 8.43 f 0.82 7.2 f 0.2 
Db  CAMP, 0.8 mM 3.60 * 0.21 4.30 f 0.27 97.8 f 4.5 
Db CAMP, 0.8 mM + imipramine, l ( r  M 26.4 f 1.7 4.27 f 0.23 8.21 k 0.48 
Normal cell strain ACS, sixth passage was the target culture. CTAP was derived from the HEp-? cell strain. Data 
are expressed as mean % 1 SD. 
CTAP to synovial cultures, there was 67Y0, 94%, and 
5770 suppression, respectively, of incremental hyaluro- 
nate over the first 16 hours. Media were changed and 
the inhibitory effect of propranolol and imipramine 
decreased in the ensuing 24 hours. Ethacrynic acid 
treated cultures, on the other hand, showed progres- 
sive inhibition of incremental hyaluronate synthesis, 
even with omission of the drug. Addition of all three 
drugs 16 hours after CTAP led to a 50-76y0 inhibi- 
tion of incremental hyaluronate synthesis in activated 
cultures, providing further evidence that these agents 
exert some inhibitory action subsequent to the initi- 
ating membrane effects. 
DISCUSSION 
Many pharmacologic agents used in this study 
inhibited primarily the incremental hyaluronate syn- 
thesis component of synovial cell activation and had 
little or no effect on CTAP-accelerated glycolysis. 
Beta-adrenergic blocking agents with this capacity in- 
cluded dl-propranolol, d-propranolol, alprenolol, and 
butoxamine. Alpha-adrenergic blocking agents that 
inhibited incremental hyaluronate synthesis included 
phentolamine, chlorpromazine, haloperidol, and phen- 
oxybenzamine. Although beta-adrenergic blocking 
agents had little capacity to inhibit CTAP-stimulated 
glycolysis, in higher concentrations (1 x lo-' M ) ,  they 
did modestly stirnitlate glucose consumption and lac- 
tate formation in their own right. In  like manner, 
alpha-adrenergic blocking agents failed to block the 
glycolytic component of synovial cell activation. Imi- 
pramine, an  antidepressant drug, resembles the pheno- 
thiazine drugs in many of its actions (19). When added 
to cultured human synovial cells, imipramine (1 x 
lo-' M )  blocked CTAP-induced incremental hya- 
luronate synthesis, but not incremental glycolysis. As 
with adrenergic blocking agents, it modestly stimu- 
lated glucose uptake and lactate formation when 
added alone to synovial cultures. 
Ethacrynic acid (0.5 to 1.0 X M )  re- 
sembled conventional antirheumatic drugs in  that it 
markedly suppressed both CTAP-induced increments 
Table 4. Eflect of Ethacrynic Acid on Synouial Cell Activation 
Additives 
Hyaluronic Acid 
Glucose Uptake Lactate Output Synthesis Rate 
(rmoles/mg cell (pmoles/mg cell (pgHA/mg cell 
protein/24 hr) protein/24 hr) protein/24 hr) 
Vehicle 3.14 2 0.28 9.90 f 0.23 13.5 
CTAP* 10.90 f 2.18 22.39 f 4.06 40.4 * 7.7 
CTAP + ethacrynic acid, 0.83 X lo4 M 1.4 f 1.3 4.36 f 2.37 13.83 -C 1.70 
Vehicle+ 
Dibutyryl CAMP, 0.8 mM 
Ethacrynic acid 0.83 X lo--' M 
Ethacrynic acid 0.83 X lo+ M + 
dibutyryl CAMP, 0.8 mM 
1.56 k 0.20 4.13 +- 0.16 7.7 f 0.6 
3.74 f 0.18 7.06 f 0.12 60.9 f 1.8 
2.25 & 0.24 6.31 * 0.58 4.5 +- 0.4 
2.76 & 0.17 7.92 f 0.29 4.6 f 0.2 
Data are expressed as the mean & SEM of quadruplicate observations. 
If both Db CAMP and ethacrynic acid were used, they were added nearly simultaneously. 
*CTAP used in each flask was extracted from 108 normal human leukocytes. The  target culture was normal synovial 
cell strain ACS, fourth subculture. CTAP and drugs were added in that sequence with only minutes intervening 
between the agcnts. 
+The target culture for this assay was the normal synovial cell strain RN, sixth subculture. 
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Table 5. Effect of T i m e  of Addition on “Antiactivating” Capacity of Propranolol, Imipramine, and Ethacrynic Acid 
Time of 
Addition 
Hyaluronic Acid Synthesis Rate (fig/mg cell protein/24 hr) 
Culture of Drug First Time Period Percent Second Time Period Percent 
(0-16 hr) Suppression (16-40 hr) Suppression Additives (hr) 
Vehicle 
Propranolol, 10- M 
Imipramine, lo-‘ M 
Ethacrynic acid, 0.5 X lo+ M 
CTAP* 
CTAP + propranolol, lo-‘ M 
CTAP + imipramine, lo--‘ M 












34.7 * 5.7 
25.5 * 0 
20.5 t 3.1 
21.5 -t 1.9 
63.4 k 4.8 
41.2 t 4.8 
71.9 k 0.9 
36.5 f 7.2 
58.5 f 6.4 
46.9 -t 3.4 
58.2 f 4.1 
22.7 f 1.3 
14.4 f 3.2 
16.8 f 3.1 
8.5 f 0.7 
92.6 f 10.3 
71.5 f 7.2 
59.4 f 10.6 
45.0 t 6.8 
39.3 * 8.9 
13.1 5 4.3 












Medium was removed from all cultures at  16 hours (first time period), completely replaced. and then removed again 24 hours later 
(second time period). Drugs wcre added at zcro time (along with CTAP) or a t  the 16-hour point. Clearly, the inhibitory agents 
blocked activation whether added early or late, and in the former case the effect was not reversed by changing the medium and 
omitting the drugs. 
*CTAP was always added at zero time. T h e  preparation was derived from the non-erythroid cells of dog spleen. 
in hyaluronate synthesis and glycolysis. When imip- 
ramine and propranolol-treated cultures promptly 
escaped from drug effects on omission of the agents, 
etliacrynic acid-induced suppression persisted for at 
least 24 hours after the culture was changed with 
drug-free media. 
Procaine and lidocaine were studied because 
they share the “membrane-stabilizing” and local anes- 
thetic properties found with adrenergic blocking 
agents, altliougli lacking specific receptor site blocking 
properties. Higher concentrations (1 x M )  of 
these local anesthetics were required to inhibit CTAP- 
induced incremental hyaluronate synthesis than was 
the case with adrenergic blocking agents (1 x M 
to 1 x lo-‘ M ) .  Tlie dimetliyl quaternary derivative 
of propranolol (U M-272), which lacks adrenergic 
blocking and local anesthetic activity, is also a very 
weak inhibitor of synovial cell activation. 
Some of the known properties of these drugs 
and their efficacy as inhibitors of synovial cell activa- 
tion are compared in Table 6. It seems clear that the 
“antiactivation” effect of tlie various drugs is un- 
related to their atlrenergic blocking properties, be- 
cause alpha, beta,,,, beta, agents, and some drugs 
without adrenergic activity, are equally effective in 
blocking CTAP-induced incremental Iiyaluronate syn- 
thesis. Furthermore, the concentrations required to 
inhibit incremental liyaluronate synthesis were several 
orders of magnitude higher than would be expected 
for classic adrenergic receptor site blockade. Lastly, it 
was clear that the agents could be added to synovial 
cultures several hours after the CTAP agonist, pre- 
sumably long after cell membrane receptor site initia- 
tory phenomena, and still inhibit CTAP-induced in- 
cremental hyaluronate synthesis. The  argument that 
beta-adrenergic blocking agents act by interfering 
with tlie generation of intracellular cyclic AMP ap- 
pears to be rendered moot by these observations. How- 
ever, if one entertains a model wherein hormone (or 
other agonist) receptors exist separately from the cata- 
lytic site, there might be direct inhibition of adenyl 
cyclase analogous to that reportedly caused by pheno- 
tliiazines in thyroid, adrenal, and hepatic tissue (20). 
It seems unlikely, however, that inhibition of adenyl 
cyclase (and consequent reduction in intracellular 
cyclic AMP) is a critical factor in the pharniacologic 
effects observed in the synovial culture system de- 
scribed here. I n  support of this position are the ob- 
servations tliat dl-propranolol inhibited both PGE, 
and dibutyryl cyclic AMP-stimulated hyaluronate syn- 
thesis in synovial cultures, and that imipramine and 
ethacrynic acid depressed dibutyryl cyclic AMP-stim- 
ulated liyaluronate formation. In  summary, it appears 
that most ot the pharmacologic agents studied may 
act late in the synovial activation sequence. This late 
actio:i may interfere with the synthesis of liyaluronate, 
or conceivably accelerate its degradation. 
Most of the agents capable of inhibiting CTAP- 
induced incremental hyaluronate synthesis have local 
anesthetic arid membrane-stabilizing activity. There 
is thought to he a close correlation between tlie ability 
of agents to stabilize erythrocytes against hypotonic 
liemolysis and their potency as local anesthetics (2 1). 
Bipliasic patterns of stabilization and lysis have been 
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Table 6. Comparison of Several Pharmalogic Agents 
Adrenergic Local Membrane Concentration Required 
Blocking Anesthetic Stabilizing Antiinflammatory to Inhibit CTAP-Induced 




























0 + + 
0 + + 
+ + + + 
0 + + + + 
0 + + 
1 x  1 0 - M  
1 x 1 0 - M  
1 x 1 0 - M  
N o  effect 
1 x  1 W M  
1 x 1 0 - M  
5 X 1 0 d M  
1 x 10-4.44 
5 x 10-M 
1 x l F M  
1 x 1 F M  
1 x l F M f  
*A dash indicates that no data wcre avai1al)le. 
fMinor effect. 
demonstrated for several local anesthetics, alcohols, 
steroid hormones, antl phenothiazines using erythro- 
cyte and lysosomal membranes as indicator systems 
(21). Chlorpromazine for example shows activity as a 
stabilizer of lysosomal membranes starting near 5 x 
10-5 M ,  and reaches a maximum near 5 x lo-' M ,  
with rapid impairment of membrane integrity (lysis) 
at slightly higher concentrations. The  chlorpromazine 
concentration required to inhibit CTAP-induced in- 
cremental hyaluronate formation corresponds closely 
with that required to provide maximum membrane 
stabilization. Membrane stabilization involves changes 
in physical properties, including increased mechanical 
strength, expansion, antl altered permeability with 
decreased transmembranal Hux of sodium and potas- 
sium (21). In  view of the likely importance of mem- 
brane-associated steps in hyaluronic acid biosynthesis, 
it is perhaps not unreasonable to expect agents acting 
at  this level to interfere with hyaluronate synthesis. 
Etliacrynic acid appears to be set apart from 
the other agents studied, not only providing more 
complete inhibition of activation effects, but being 
less easily reversible. Diverse actions of ethacrynic 
acid that have been reported include: inhibition of 
potassium activated p-nitrophenylphospliatase and cer- 
tain ATPases in normal white blood cells (229, inhibi- 
tion of cholera exotoxin-induced secretion of gut 
electrolytes (23), and inhibition of the inflammatory 
process (24). Studies on cotton pellet granulomas in 
rats indicated that ethacrynic acid substantially de- 
pressed granuloma weight (24). The  reversal of this 
antiinflammatory effect with cysteine was thought to 
support a mechanism of action involving interaction 
with sulfhydryl groups. Among the other agents 
studied here, at least two have been shown to possess 
antiinflammatory activity in vivo. Imipramine inhibits 
paw edema in the rat and inHammatory reactions in- 
duced by formalin, egg white, and croton oil (19). 
Propranolol in doses of 0.5 to 2.5 mg/l00 g appeared 
to inhibit formaldehyde-induced arthritis in rats (25). 
With the perspective provided by the foregoing ob- 
servations, i t  may be useful to observe carefully pa- 
tients treated with these pharmacologic agents for evi- 
dence of altered connective tissue metabolism and re- 
sponse to inflammatory stimuli. 
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